Loading provider…
Loading provider…
Infectious Disease Physician in Rochester, NY
NPI: 1649491705Primary Practice Location
STRONG MEMORIAL HOSPITAL
601 Elmwood Ave, Rochester, NY
Primary Employer
Infectious Disease Clinical
urmc.rochester.edu
HQ Phone
Get MD Sonal's Phone Numberphone_androidMobile
Get MD Sonal's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
New York University Grossman School of Medicine
Medical School
Until 1989
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 12 | 12 |
| 2 | 99231Subsequent hospital inpatient care, typically 15 minutes per day | 11 | 17 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 11 | 13 |
Authors: Brenon, Jessa R, Shulder, Stephanie E, Munsiff, Sonal S, Burgoyne, Colleen M, Nagel, Angela K, Pillinger, Kelly E
Journal: Antimicrob Steward Healthc Epidemiol
Publication Date: 2021-10-22
Daily fosfomycin versus levofloxacin for complicated urinary tract infections.
Authors: Yohei Doi, Patricia Winokur, Scott Evans, Vance Fowler, Michael Keefer, Nadine Rouphael
Journal: mBio
Publication Date: 2023-09-12
Authors: King, L, Munsiff, S S, Ahuja, S D
Journal: Int J Tuberc Lung Dis
Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Intervention / Treatment: DRUG: Doravirine 100 Mg, DRUG: Integrase strand transfer inhibitors, DRUG: Tenofovir alafenamide/emtricitabine, DRUG: tenofovir disproxil fumarate/emtricitabine
Lead Sponsor: Sanofi Pasteur, a Sanofi Company
Collaborators: GlaxoSmithKline
Intervention / Treatment: BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03, BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2, BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4